Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phenyramidol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | FDPS | P14324 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | FABP1 | P07148 | 1/20 | 0.50 |
| ▸ | FABP6 | P51161 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 9/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.49 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenyramidol SCHEMBL121004 | 1.00 | CYP2D6 (0.97) | CYP2D6KDM4EFDPSL3MBTL1FABP1 | |
| Phenyramidol SCHEMBL21963 | 0.98 | CYP2D6 (1.00) | CYP2D6KDM4EFDPSL3MBTL1FABP1 | |
| Phenyramidol SCHEMBL13310219 | 0.98 | CYP2D6 (1.00) | CYP2D6KDM4EFDPSL3MBTL1FABP1 | |
| Phenyramidol SCHEMBL29500950 | 0.98 | CYP2D6 (1.00) | CYP2D6KDM4EFDPSL3MBTL1FABP1 | |
| Phenyramidol SCHEMBL13310227 | 0.98 | CYP2D6 (1.00) | CYP2D6KDM4EFDPSL3MBTL1FABP1 | |
| Phenyramidol SCHEMBL20769334 | 0.97 | CYP2D6 (0.97) | CYP2D6KDM4EFDPSL3MBTL1FABP1 | |
| Phenyramidol SCHEMBL3446649 | 0.92 | CYP2D6 (0.88) | CYP2D6KDM4EFDPSL3MBTL1FABP1 | |
| SCHEMBL9566716 | 0.86 | CYP2D6 (0.77) | CYP2D6KDM4EFDPSFABP1FABP6 | |
| Fenyripol SCHEMBL120829 | 0.83 | CYP2D6 (0.68) | CYP2D6KDM4EL3MBTL1FAAHAOC3 | |
| Phenyramidol SCHEMBL22718457 | 0.83 | CYP2D6 (0.71) | CYP2D6KDM4EFDPSFAAHAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170161-A1 | INHIBIN SUBUNIT BETA E INHIBITOR AND METHODS OF USE THEREOF | RISEN (SHANGHAI) MEDICINAL TECHNOLOGY CO., LTD. (CN) | 2025-05-29 | — | — | US | disclosed |
| CN-119519900-A | Rate de-matching method, apparatus, device, medium and computer program product | 广东杰创智能科技有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-117396205-A | Method for titrating Mitapilar | 安吉奥斯医药品有限公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-116568281-A | Pharmaceutical preparation | 安吉奥斯医药品有限公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-109312306-B | Method for producing retinal tissue | 住友制药株式会社 | 2023-05-09 | — | — | CN | disclosed |
| CN-112824229-B | Avionics function test testing system | 中国商用飞机有限责任公司 | 2023-01-17 | — | — | CN | disclosed |
| CN-114026773-A | Communication failure indication between a primary controller and a secondary controller in a secondary controlled flyback converter | 赛普拉斯半导体公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170161-A1 | INHIBIN SUBUNIT BETA E INHIBITOR AND METHODS OF USE THEREOF | INHA, IGF2BP1, IGF2BP2 | CYP2D6 4711/4885KDM4E 2066/4885FDPS 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.